基础与高级生命支持终止复苏规则的诊断性能:系统评价与诊断性Meta分析
BLS与ALS规则的汇总特异性分别为0.95(0.89-0.98)和0.98(0.95-1.00),PPV分别为0.99(0.99-1.00)和1.00(0.99-1.00)。非西方地区特异性显著低于西方地区:BLS规则0.84(0.73-0.92)vs 0.99(0.97-0.99),p<0.001;ALS规则0.94(0.87-0.97)vs 1.00(0.99-1.00),p<0.001。在非西方地区,每100名潜在存活者中分别有16名(BLS)或6名(ALS)符合终止复苏标准;Meta回归显示现场除颤率越低,规则性能越差。
要点
- BLS规则汇总特异性0.95(0.89-0.98)、PPV 0.99(0.99-1.00);ALS规则特异性0.98(0.95-1.00)、PPV 1.00(0.99-1.00)。
- 非西方地区BLS规则特异性0.84(0.73-0.92)显著低于西方地区0.99(0.97-0.99),p<0.001。
- 非西方地区ALS规则特异性0.94(0.87-0.97)显著低于西方地区1.00(0.99-1.00),p<0.001。
- 非西方地区每100名潜在存活者中,BLS规则有16名、ALS规则有6名符合终止复苏标准。
- Meta回归显示现场除颤率越低,BLS与ALS终止复苏规则的诊断性能越差。
适用人群与场景
- 非创伤性成人心脏骤停患者,涉及院前终止复苏决策场景。
诊断标准与关键阈值
- BLS终止复苏规则与ALS终止复苏规则,目标PPV≥99%且特异性≥99%。
研究设计与关键结果
- BLS规则汇总特异性0.95(0.89-0.98),PPV 0.99(0.99-1.00);ALS规则汇总特异性0.98(0.95-1.00),PPV 1.00(0.99-1.00)。
- 非西方地区vs西方地区BLS规则特异性0.84(0.73-0.92)vs 0.99(0.97-0.99),p<0.001。
- 非西方地区vs西方地区ALS规则特异性0.94(0.87-0.97)vs 1.00(0.99-1.00),p<0.001。
- 非西方地区每100名潜在存活者中,BLS规则有16名、ALS规则有6名符合终止复苏标准。
- Meta回归显示现场除颤率较低的设置中规则性能下降。
证据类型、等级与局限
- 证据类型:系统评价与诊断性Meta分析,遵循PRISMA-DTA指南。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管总体PPV高,但BLS与ALS终止复苏规则在非西方地区和现场除颤率低的人群中诊断性能存在临床重要差异。
- 作者认为,亟需提高对规则诊断性能差异的认识,并有必要对规则进行本地验证,以防止在现场终止潜在存活者的复苏。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 2 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
AIM: To minimize termination of resuscitation (TOR) in potential survivors, the desired positive predictive value (PPV) for mortality and specificity of universal TOR-rules are ≥99%. In lack of a quantitative summary of the collective evidence, we performed a diagnostic meta-analysis to provide an overall estimate of the performance of the basic and advanced life support (BLS and ALS) termination rules.
DATA SOURCES: We searched PubMed/EMBASE/Web-of-Science/CINAHL and Cochrane (until September 2019) for studies on either or both TOR-rules in non-traumatic, adult cardiac arrest. PRISMA-DTA-guidelines were followed.
RESULTS: There were 19 studies: 16 reported on the BLS-rule (205.073 patients, TOR-advice in 57%), 11 on the ALS-rule (161.850 patients, TOR-advice in 24%). Pooled specificities were 0.95 (0.89-0.98) and 0.98 (0.95-1.00) respectively, with a PPV of 0.99 (0.99-1.00) and 1.00 (0.99-1.00). Specificities were significantly lower in non-Western than Western regions: 0.84 (0.73-0.92) vs. 0.99 (0.97-0.99), p < 0.001 for the BLS rule. For the ALS-rule, specificities were 0.94 (0.87-0.97) vs. 1.00 (0.99-1.00), p < 0.001. For non-Western regions, 16 (BLS) or 6 (ALS) out of 100 potential survivors met the TOR-criteria. Meta-regression demonstrated decreasing performance in settings with lower rates of in-field shocks.
CONCLUSIONS: Despite an overall high PPV, this meta-analysis highlights a clinically important variation in diagnostic performance of the BLS and ALS TOR-rules. Lower specificity and PPV were seen in non-Western regions, and populations with lower rates of in-field defibrillation. Improved insight in the varying diagnostic performance is highly needed, and local validation of the rules is warranted to prevent in-field termination of potential survivors.
参考来源
- Nas J, Kleinnibbelink G, Hannink G, et al. Diagnostic performance of the basic and advanced life support termination of resuscitation rules: A systematic review and diagnostic meta-analysis. Resuscitation. 2019. PMID: 31887367. doi:10.1016/j.resuscitation.2019.12.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。